SCHEMBL5855718

SCHEMBL5855718

COC(=O)C(C)(C)OCCCCCCc1coc(-c2ccc(F)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGD P15428 1/20 0.43
PPARA Q07869 4/20 0.42
PPARG P37231 3/20 0.42
PPARD Q03181 1/20 0.41
HDAC1 Q13547 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
PDE4B Q07343 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5855890 1.00 LMNA (0.45) LMNAGAATSHRKMT2AHPGD
SCHEMBL5858411 0.90 PPARA (0.42) LMNAPPARAPPARGPPARDHDAC1
SCHEMBL5858343 0.89 PPARA (0.53) LMNAGAATSHRKMT2APPARA
SCHEMBL5857569 0.89 PPARA (0.53) LMNAGAATSHRKMT2AHPGD
SCHEMBL5858320 0.89 PPARA (0.53) LMNAGAATSHRKMT2APPARA
SCHEMBL5858433 0.89 PPARA (0.53) LMNAGAATSHRKMT2APPARA
SCHEMBL5855844 0.89 PPARA (0.53) LMNAGAATSHRKMT2AHPGD
SCHEMBL5858400 0.80 PPARG (0.66) KMT2APPARAPPARGPPARD
SCHEMBL5857029 0.79 PPARG (0.64) LMNAPPARAPPARGPPARD
SCHEMBL5856339 0.79 PPARG (0.64) LMNAPPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB LMNA 606/4885GAA 565/4885TSHR 1666/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE LMNA 601/4885GAA 804/4885TSHR 2487/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC LMNA 636/4885GAA 780/4885TSHR 2672/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC LMNA 636/4885GAA 780/4885TSHR 2672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.